open access

Ahead of print
Original papers
Published online: 2017-06-01
Submitted: 2016-07-01
Accepted: 2016-10-31
Get Citation

Thyroid cancer post radioactive iodine treatment for hyperthyroidism (case series and review of the literature)

Abdallah A Al Eyadeh,, Khaldon M Al-Sarihin,, Suzan M Etewi, Ahmed A Al-Omari, Rania Atallah Al-Asa'd, Fares Halim Haddad
DOI: 10.5603/EP.a2017.0037

open access

Ahead of print
Original papers
Published online: 2017-06-01
Submitted: 2016-07-01
Accepted: 2016-10-31

Abstract

Introduction: To assess the rate of thyroid cancer and mortality rate in a cohort of patients who received RAI131 treatment for hyperthyroidism and to report the index cases’ characteristics and management

Material and methods: A cohort of 264 patients who received RAI131 treatment for different causes of thyrotoxicosis were followed up over a period of 18 years (1996–2014) by physical exam, radiological evaluation and serial thyroid function tests.

Results: During the follow up period, three cases of thyroid cancer were identified. The prevalence of thyroid cancer is 1.136% of cases who received RAI131. The relative risk is 378.79 (95% CI: 76.8 < RR < 1868.23). P value is < 0.0000004 and the SMR is 1.99/1000.

Conclusions: The prevalence of thyroid cancer is 1.136% in the cohort of patients treated with RAI131. Despite no direct cause effect relationship between RAI and thyroid cancer could be established, these cases highlights the importance of life long surveillance of patients who receive RAI131.

Abstract

Introduction: To assess the rate of thyroid cancer and mortality rate in a cohort of patients who received RAI131 treatment for hyperthyroidism and to report the index cases’ characteristics and management

Material and methods: A cohort of 264 patients who received RAI131 treatment for different causes of thyrotoxicosis were followed up over a period of 18 years (1996–2014) by physical exam, radiological evaluation and serial thyroid function tests.

Results: During the follow up period, three cases of thyroid cancer were identified. The prevalence of thyroid cancer is 1.136% of cases who received RAI131. The relative risk is 378.79 (95% CI: 76.8 < RR < 1868.23). P value is < 0.0000004 and the SMR is 1.99/1000.

Conclusions: The prevalence of thyroid cancer is 1.136% in the cohort of patients treated with RAI131. Despite no direct cause effect relationship between RAI and thyroid cancer could be established, these cases highlights the importance of life long surveillance of patients who receive RAI131.

Get Citation

Keywords

toxic multinodular goiter, thyroid cancer, radioactive iodine

About this article
Title

Thyroid cancer post radioactive iodine treatment for hyperthyroidism (case series and review of the literature)

Journal

Endokrynologia Polska

Issue

Ahead of print

Published online

2017-06-01

DOI

10.5603/EP.a2017.0037

Keywords

toxic multinodular goiter
thyroid cancer
radioactive iodine

Authors

Abdallah A Al Eyadeh,
Khaldon M Al-Sarihin,
Suzan M Etewi
Ahmed A Al-Omari
Rania Atallah Al-Asa'd
Fares Halim Haddad

Important: This website uses cookies.tanya dokter More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

Via MedicaWydawcą serwisu jest  "Via Medica sp. z o.o." sp.k., ul. Świętokrzyska 73, 80–180 Gdańsk

tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail:  viamedica@viamedica.pl